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  We examined the effects of peripherally or centrally administered botulinum neurotoxin type A (BoNT-A) 
on orofacial inflammatory pain to evaluate the antinociceptive effect of BoNT-A and its underlying 
mechanisms. The experiments were carried out on male Sprague-Dawley rats. Subcutaneous (3 U/kg) 
or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced 
nociceptive response in the second phase. Both subcutaneous (1 or 3 U/kg) and intracisternal (0.3 or 
1 U/kg) injection of BoNT-A increased the latency of head withdrawal response in the complete Freund’s 
adjuvant (CFA)-treated rats. Intracisternal administration of N-methyl-D-aspartate (NMDA) evoked 
nociceptive behavior via the activation of trigeminal neurons, which was attenuated by the subcutaneous 
or intracisternal injection of BoNT-A. Intracisternal injection of NMDA up-regulated c-Fos expression 
in the trigeminal neurons of the medullary dorsal horn. Subcutaneous (3 U/kg) or intracisternal (1 
U/kg) administration of BoNT-A significantly reduced the number of c-Fos immunoreactive neurons 
in the NMDA-treated rats. These results suggest that the central antinociceptive effects the peripherally 
or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal 
neurons. Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the 
treatment of orofacial chronic pain conditions.
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INTRODUCTION
  Botulinum neurotoxins (BoNTs), synthesized by the 
anaerobic bacterium Clostridium botulinum, consist of a 
heavy and light chain linked together by a disulfide bond 
[1]. BoNTs inhibit acetylcholine release from the peripheral 
nerve terminal by the cleavage of the soluble N-ethylmalei-
mide-sensitive factor attachment receptor (SNARE) protein 
complex, which is required for neurotransmitter release [2,3]. 
Recent evidence support that botulinum neurotoxin type A 
(BoNT-A) can be used for the treatment of various pain synd-
romes. In clinical practice, BoNT-A treatment was effective 
in alleviating chronic tension-type headache [4], chronic low 
back pain [5], musculoskeletal pain [6], migraine [7,8], and 
myofacial pain [9]. In animal studies, peripheral applica-
tion of BoNT-A into the rat paw pad significantly reduced 
the enhanced sensitivity to mechanical and thermal stimuli 
provoked by carrageenan or capsaicin injections [10], and 
reduced the formalin-induced nociceptive behaviors [11,12]. 
  In addition to its peripheral actions, central administration 
of BoNT-A also modulates pain processing. Intrathecal ad-
ministration of BoNT-A significantly decreased the formal-
in-induced nociceptive responses in mice [12,13] and the hy-
persensitivity to acidic saline-induced bilateral pain [14]. 
These results suggest that central administration of BoNT-A 
induces antinociception through blockade of neurotransmitter 
release at the central terminals of primary afferent nerves. 
However, these results did not reveal whether BoNT-A acts 
on neurons in the spinal cord beyond the primary afferent 
nerve fibers. 
  Previous studies also demonstrated that BoNT-A attenu-
ated orofacial nociception. Intradermal injection of BoNT-A 
in the innervation area of the infraorbital branch of the 
trigeminal nerve alleviated mechanical allodynia in rats 
with chronic constriction injury of the infraorbital nerve 
[15]. In a clinical study, BoNT-A suppressed experimental 
trigeminal/cervical pain evoked by the intradermal injection 
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of capsaicin into the forehead [16]. Moreover, BoNT-A was 
effective in patients with chronic facial pain including tem-
poromandibular joint syndrome, postsurgical pain syndromes, 
essential headache, and idiopathic trigeminal neuralgia [17]. 
These results suggest that BoNT-A might be beneficial for 
the modulation of orofacial pain. However, the application 
of BoNT-A is very limited for the treatment of orofacial 
nociception. 
  Here we examined the effects of peripherally and cen-
trally administered BoNT-A on the orofacial formalin re-
sponse and complete Freund’s adjuvant (CFA)-induced ther-
mal hypersensitivity in rats. We also investigated the effect 
of peripherally and centrally administered BoNT-A on the 
intracisternal NMDA-induced nociceptive behavior by the 
direct activation of trigeminal neurons. To confirm partic-
ipation of trigeminal neurons in BoNT-A-induced anti-
nociception, we evaluated changes in c-Fos expression in 
the medullary dorsal horn after the subcutaneous or intra-
cisternal injection of BoNT-A. 
METHODS
Animals 
  The experiments were carried out on male Sprague-Dawley 
rats weighing between 230 and 280 g. The rats were main-
tained at a constant temperature and under a standard 12 
h/12 h light/dark cycle. Food and water were freely available. 
All procedures including the use of animals were approved 
by the Institutional Care and Use Committee of the School 
of Dentistry, Kyungpook National University (Daegu, Korea). 
Experiments were carried out in accordance with the eth-
ical guidelines for the investigation of experimental pain 
in conscious animals issued by the International Association 
for the Study of Pain (1982). All experiments were performed 
in a blinded manner.
Intracisternal catheterization
  For intracisternal injections, the rats were anesthetized 
with a mixture of ketamine (40 mg/kg) and xylazine (4 mg/kg). 
The anesthetized rat was mounted onto a stereotaxic frame. 
A polyethylene tube (PE10; Clay Adams, Parsippany, NJ) 
was implanted, as described previously [18-20]. The poly-
ethylene tube was inserted through a tiny hole made in the 
atlanto-occipital membrane and dura using a 27-gauge sy-
ringe needle. The tip of the cannula was placed at the obex 
level. The PE10 tube was guided subcutaneously to the top 
of the skull and secured in place with a stainless steel screw 
and dental acrylic resin. The drugs were administered in-
tracisternally after a 72-h recovery period following surgery.
Orofacial pain models
  Orofacial formalin response: The formalin test was per-
formed to assess the inflammatory nociceptive response in 
the orofacial region of rats [21-23]. Briefly, 40 μl of 3% 
formalin was applied subcutaneously into the vibrissa pad. 
For each animal, the number of noxious behavioral re-
sponses, including rubbing of the facial region proximal to 
the injection site, was recorded over 9 sequential 5-min 
intervals. The nociceptive responses were recorded for 45 
min after the formalin injection. The orofacial formalin re-
sponses showed 2 distinct phases; an early, short response 
(0 to 10 min, first phase) and a continuous, prolonged re-
sponse (11 to 45 min, second phase) that were separated 
by an interval of relative inactivity [24,25]. 
  CFA-induced thermal hypersensitivity: CFA (Sigma-Aldrich, 
St Louis, MO) was used to induce chronic inflammation. 
A 40 μl of CFA were injected subcutaneously into the left 
vibrissa pad. A previous study reported that the subcuta-
neous injection of CFA induced thermal hypersensitivity 
within 3 days, which peaked on postoperative day 5, and 
returned to the preoperative levels on postoperative day 14 
[26]. To evaluate heat hypersensitivity, each rat was placed 
in a customized cylindrical acrylic rodent restrainer (height 
40∼60 mm, length 70∼120 mm). The restrainer had a hole 
on the top to allow thermal stimulation of the head and 
head withdrawal. Each restrainer was placed in a darkened 
and noise-free room, and animals were habituated to the 
room and apparatus for a minimum of 30 min before the 
experiment. After the application of radiant heat, the la-
tency for head withdrawal was recorded as described pre-
viously [27-29]. Heat stimulus was applied using an infra-
red thermal stimulator (Infrared Diode Laser, LVI-808-10, 
LVI tech, Seoul, Korea) set to 11 W and 18.1 A. When the 
distance between the heat source and vibrissa pad was 10 
cm, we noticed a stable head withdrawal with a latency 
of approximately 12 s. Thermal hyperalgesia was tested 1, 
3, 5, 7, 9, 11, 13, 15, and 18 days after CFA injection. The 
latency of head withdrawal was recorded three times with 
5 min intervals. A cut-off time of 20 sec was used in these 
experiments to prevent possible tissue damage.
  Nociceptive behavior induced by intracisternally injected 
NMDA: Wilcox (1988) first demonstrated that intrathecal 
administration of excitatory amino acids including NMDA 
produced behavior like that following the presentation of 
some noxious stimuli [32]. NMDA-induced nociceptive be-
havior was blocked pretreatment with DAMGO, a μ-opioid 
agonist. Previous studies also demonstrated that intra-
thecal or intracisternal administration of NMDA induced 
nociceptive behavior by activating spinal or trigeminal neu-
rons [30,31,33]. In the present study, the orofacial noci-
ceptive behavioral responses were monitored after the in-
tracisternal injection of NMDA. Microinjection of NMDA 
(0.5 μg/7 μl) through the implanted PE10 tube induced 
an intense rubbing behavior exclusively in the orofacial 
region. For each animal, the number of rubbing actions tar-
geting the facial region was recorded in freely moving rats.
Administration of BoNT-A
  The present study investigated the peripheral and cen-
tral effects of BoNT-A using orofacial pain models. We in-
jected BoNT-A (1 or 3 U/kg, 30 μl) subcutaneously into 
the vibrissa pad 3 days before formalin, CFA, or NMDA 
injections to determine the peripheral effects of BoNT-A. 
BoNT-A (0.3 or 1 U/kg, 10 μl) was injected intracisternally 
3 days before formalin, CFA, or NMDA injections with a 
Hamilton syringe connected to the implanted PE10 tube in 
freely moving rats to determine the central effects of BoNT-A. 
Hundred units of BoNT-A (BotulaxⓇ, Hugel Inc, Chuncheon, 
Korea) were diluted in 1 ml of saline. 
Immunohistochemical staining of c-Fos
  To examine whether subcutaneous or intracisternal in-
jection of BoNT-A affects trigeminal neurons, we evaluated 
the changes in c-Fos expression in the medullary dorsal 
horn induced by NMDA injection in rats. BoNT-A was in-
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Fig. 1. Effects of the subcutaneous (A) or intracisternal (B) injection 
of botulinum neurotoxin type A (BoNT-A) on the formalin-induced 
nociceptive behavior. Subcutaneous injection (1 or 3 U/kg) and 
intracisternal (0.3 or 1 U/kg) administration of BoNT-A attenuated 
the formalin-induced nociceptive behavior in the second phase. 
*p＜0.05 vehicle vs. BoNT-A treated group, n=8 animals per group.
jected subcutaneously (3 U/kg) or intracisternally (1 U/kg) 
3 days before NMDA injection. Rats (n=5 per group) were 
anesthetized, and then perfused transcardially with 0.9% 
saline, followed by 4% paraformaldehyde in 0.1 M phos-
phate buffer (PB, pH 7.4). The caudal medulla was dis-
sected and postfixed in the same fixative at 4oC for 2 h, 
and incubated with 30% sucrose in 0.1 M PB overnight. 
Specimens were frozen and cut into 30 μm thick transverse 
sections. Free-floating sections were rinsed in phosphate-buf-
fered saline (PBS) and blocked with 2.5% normal horse se-
rum (Vector Laboratories, Burlingame, CA) for 1 h at room 
temperature. The sections were incubated at 4oC overnight 
with the rabbit polyclonal anti-c-Fos antibody (1:1000, 
Abcam, Cambridge, MA). Sections were then incubated in 
peroxidase-conjugated anti-rabbit IgG (Vector Laboratories) 
for 2 h at room temperature. After washing, sections were 
incubated in a buffer containing diaminobenzidine (DAB) 
and hydrogen peroxide (pH 7.5) for approximately 1 min 
(Vector Laboratories). Stained sections were analyzed using 
a microscope (BX 41 and U-RFL-T, Olympus, Tokyo, Japan). 
Neurons immunopositive for c-Fos were counted in the su-
perficial laminae (I-II) of the medullary dorsal horn in three 
sections. 
Statistical analysis 
  Statistical analysis of behavioral data in the CFA model 
was carried out using repeated measures analysis of var-
iance (RM-ANOVA) followed by Holm-Sidak post hoc test. 
Behavioral data between the formalin and NMDA-treated 
groups were evaluated using one-way analysis of variance 
(ANOVA) followed by Holm-Sidak post hoc test. In all stat-
istical comparisons, p＜0.05 was used as criterion for 
significance. All data are presented as mean±standard er-
ror of the mean (SEM). 
RESULTS
Effects of BoNT-A on the orofacial formalin-induced 
response
  Effects of BoNT-A on the orofacial formalin-induced re-
sponse are illustrated in Fig. 1. Subcutaneous injection of 
40 μl of 3% formalin evoked a nociceptive behavior. Subcu-
taneous injection of 3 U/kg BoNT-A significantly inhibited 
the formalin-induced nociceptive behavior in the second 
phase (p＜0.05, Fig. 1A). However, a low dose of BoNT-A 
(1 U/kg) and vehicle did not affect the formalin-induced no-
ciceptive behavior. Intracisternal administration of vehicle 
did not affect the orofacial formalin-induced response. 
However, intracisternal administration of BoNT-A (0.3 and 
1 U/kg) significantly reduced the number of rubbing re-
sponses in the second phase evoked by the injection of for-
malin (p＜0.05, Fig. 1B). 
Effects of BoNT-A on CFA-induced thermal hyper-
sensitivity
  Fig. 2 illustrates the effects of BoNT-A on the CFA-in-
duced thermal hyperalgesia in the orofacial region. Subcu-
taneous injection of CFA evoked thermal hypersensitivity. 
Subcutaneous injection of 1 or 3 U/kg BoNT-A increased 
the latency of the head withdrawal in CFA-treated rats 
(p＜0.05, Fig. 2A). In addition, intracisternal administration 
of 0.3 or 1 U/kg BoNT-A blocked the thermal hyperalgesia 
in CFA-treated rats compared to that in vehicle treated rats 
(p＜0.05, Fig. 2B). Both the subcutaneous and intra-
cisternal injections of vehicle did not affect the head with-
drawal latency in CFA-treated rats. 
Effects of BoNT-A on the NMDA-induced nociceptive 
behavior 
  Fig. 3 illustrates the effects of BoNT-A on the nociceptive 
behavior induced by the intracisternal injection of NMDA. 
Intracisternal administration of 0.5 μg NMDA produced 
significant nociceptive behavior via the activation of trige-
minal neurons. Subcutaneous injection of 1 or 3 U/kg BoNT-A 
attenuated the NMDA-induced nociceptive rubbing response 
(p＜0.05, Fig. 3A). Then we examined the NMDA-induced 
nociceptive behavior after the intracisternal injection of 
BoNT-A. Intracisternal injection of 0.3 or 1 U/kg BoNT-A 
significantly reduced the number of rubbing induced by the 
intracisternal administration of NMDA (p＜0.05, Fig. 3B).
Effects of BoNT-A on c-Fos expression in the NM-
DA-treated rats 
  Effects of BoNT-A on c-Fos expression are illustrated in 
Fig. 4. Intracisternal injection of NMDA evoked intense 
rubbing. In addition to behavioral responses, intracisternal 
injection of 0.5 μg NMDA up-regulated c-Fos expression 
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Fig. 3. Effects of the subcutaneous (A) or intracisternal (B) injection 
of botulinum neurotoxin type A (BoNT-A) on the NMDA-induced 
nociceptive behavior. Intracisternal administration of 0.5 μg 
NMDA evoked a significant nociceptive behavior by the activation 
of trigeminal neurons. Both subcutaneous and intracisternal 
injections of BoNT-A attenuated the number of rubbing induced 
by the intracisternal injection of NMDA. *p＜0.05 vehicle vs. 
BoNT-A treated group, n=8 animals per group.
Fig. 2. Effects of the subcutaneous (A) or intracisternal (B) injection 
of botulinum neurotoxin type A (BoNT-A) on the complete Freund’s
adjuvant (CFA)-induced thermal hypersensitivity. Both subcutaneous
and intracisternal injection of BoNT-A attenuated the head 
withdrawal latency induced by CFA injection. *p＜0.05 vehicle vs. 
BoNT-A treated group, n=8 animals per group.
in the trigeminal neurons of the medullary dorsal horn. 
Most c-Fos-positive neurons were localized in the super-
ficial layer (lamina I-II). Subcutaneous injection of BoNT-A 
(3 U/kg) significantly attenuated the number of c-Fos im-
munoreactive neurons induced by the intracisternal in-
jection of NMDA (p＜0.05, Fig. 4C). Additionally, intra-
cisternal administration of BoNT-A (1 U/kg) significantly 
decreased the number of c-Fos immunoreactive neurons in 
the medullary dorsal horn (p＜0.05, Fig. 4D). 
DISCUSSION
  This is the first study demonstrating that peripheral in-
jection of BoNT-A has an antinociceptive effect on the trige-
minal neurons via transcytosed BoNT-A. We showed that 
peripheral and central administration of BoNT-A attenu-
ated the formalin-induced nociceptive behavior and CFA-in-
duced thermal hyperalgesia in the orofacial region. The tri-
geminal NMDA receptor-mediated nociceptive behavior 
was also attenuated by the peripheral and central applica-
tion of BoNT-A. Furthermore, immunohistochemical stain-
ings revealed that subcutaneous or intracisternal admin-
istration of BoNT-A downregulated c-Fos expression in the 
medullary dorsal horn. These results suggest that the cen-
tral antinociceptive effects of BoNT-A are mediated by 
transcytosed BoNT-A or direct inhibition of the trigeminal 
neurons when the peripheral or central administration of 
BoNT-A. 
  It has been well known that BoNT-A blocks acetylcholine 
release into the synaptic cleft [34,35] by the cleavage of 
SNARE protein complexes resulting in an incomplete for-
mation of the SNARE complex [3,36]. This specialized ac-
tion in the nerve terminals made BoNT-A a useful tool both 
in basic and clinical sciences for treating a variety of neuro-
muscular disorders including strabismus, blepharospasm, 
hemifacial spasm, and torticollis [37,38]. The present study 
demonstrated that subcutaneous injection of BoNT-A was 
antinociceptive in rats with orofacial formalin-induced be-
havioral responses and CFA-induced thermal hyperalgesia. 
The antinociceptive effects of peripherally administered 
BoNT-A are consistent with several previous studies [11,12, 
39,40]. The proposed underlying mechanism of the anti-
nociceptive action after peripheral injection of BoNT-A is 
the retrograde axonal transport of BoNT-A from the periph-
ery to the central terminals of the primary afferent fibers 
[41]. These results suggest that peripheral injection of 
BoNT-A evokes antinociceptive effects via the modulation 
of neurotransmitter release from the central terminals of 
the primary afferent fibers. These results are supported by 
several previous studies. Subcutaneous administration of 
BoNT-A, which reduced the formalin-induced nociceptive 
behaviors, inhibited glutamate release from the primary af-
ferent terminals [11]. In addition, application of BoNT-A 
inhibited substance P secretion in embryonic rat dorsal root 
ganglia primary neuronal cultures [42]. Therefore, these 
previous studies suggest a possible underlying mechanism 
for the antinociceptive effect of peripherally injected BoNT-A.
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Fig. 4. Effects of the subcutaneous or intracisternal injection of 
botulinum neurotoxin type A (BoNT-A) on c-Fos expression in the 
medullary dorsal horn. (A) c-Fos immunoreactive neurons in a 
naïve animal. (B) Intracisternal administration of 0.5 μg NMDA 
increased the number of c-Fos immunoreactive neurons in the 
superficial lamina I and II in the medullary dorsal horn. (C) 
Subcutaneous administration of BoNT-A (3 U/kg) decreased the 
number of c-Fos immunoreactive neurons. (D) Intracisternal 
injection of BoNT-A (1 U/kg) decreased the number of c-Fos
immunoreactive neurons. (E) The histogram shows the number of 
c-Fos immunoreactive neurons in the ipsilateral medullary dorsal 
horn. *p＜0.05 vehicle vs. BoNT-A treated group, n=5 animals per 
group. Scale bar, 100 μm.
  Interestingly, the present study demonstrated that pe-
ripherally administered BoNT-A reduced the NMDA-in-
duced nociceptive behavioral response. This suggests that 
peripheral injection of BoNT-A may affect trigeminal neu-
rons beyond the synapses of primary afferent fibers in the 
medullary dorsal horn. This behavioral evidence is con-
sistent with previous studies. Following a BoNT-A injection 
into the rat eye, catalytical active BoNT-A is transported 
from the eye to the superior colliculus via transcytosis in 
the tectal synapses [43]. After the unilateral delivery of 
BoNT-A into the hippocampus, SNAP-25 cleavage by BoNT-A 
was observed at the contralateral side [44]. However, there 
are no behavioral evidence for the antinociceptive effects 
of transcytosed BoNT-A after the peripheral injection of 
BoNT-A. Our results are the first to provide behavioral evi-
dence that transcytosed BoNT-A evoked antinociception in 
the NMDA-treated rats after peripheral injection of BoNT-A. 
Our c-Fos data confirmed the behavioral effects of periph-
erally injected and transcytosed BoNT-A. Subcutaneous in-
jection of BoNT-A attenuated the c-Fos expression evoked 
by the activation of trigeminal neurons in the medullary 
dorsal horn. 
  In addition to its peripheral action, intracisternally ad-
ministered BoNT-A inhibited the formalin-induced noci-
ceptive behavior and CFA-induced thermal hyperalgesia in 
our study. The central antinociceptive effects of BoNT-A are 
consistent with previous studies. Intrathecal administration 
of BoNT-A reduced the mechanical allodynia and thermal 
hyperalgesia induced by sciatic nerve ligation [45] and dia-
betic hyperalgesia [46] in rats. These results, taken togeth-
er with the present data, suggest that BoNT-A exerts its 
antinociceptive effects by inhibiting neurotransmitter re-
lease from the central terminals of the primary afferent 
fibers. Here we showed that intracisternal administration 
of BoNT-A significantly inhibited the NMDA-induced noci-
ceptive response. This result suggests that central admin-
istration of BoNT-A induces a strong antinociceptive effect, 
and BoNT-A-induced antinociception is mediated by the di-
rect inhibition of trigeminal neurons. This central action 
is further supported by our immunohistochemical data, 
which revealed that intracisternal injection of BoNT-A atte-
nuated the up-regulation of c-Fos expression in the medul-
lary dorsal horn evoked by the intracisternal NMDA injection. 
Moreover, we showed that the dose required for the anti-
nociceptive action of centrally injected BoNT-A is lower 
than that of peripherally injected BoNT-A. These results 
suggest that central administration of BoNT-A might be 
beneficial for treating chronic pain conditions in new ther-
apeutic targets. However, the underlying mechanisms for 
the central antinociceptive effects of BoNT-A are not clear.
  A recent study demonstrated that after the intraplantar 
injection of BoNT-A, neurons immunopositive for cl-SNAP-25 
colocalized with astrocytes, which were clearly detected in 
mice with a chronic constriction injury of the sciatic nerve 
[41]. This suggests that glial cells are engaged in mediating 
the antinociceptive effects of BoNT. However, the cellular 
mechanisms of participation of glial cells in antinociceptive 
effects of BoNT require further investigations. 
  In summary, peripheral treatment with BoNT-A attenu-
ated the formalin-induced nociceptive behavior and CFA-in-
duced thermal hyperalgesia in the orofacial region. The tri-
geminal NMDA receptor-mediated nociceptive behavior and 
c-Fos expression was attenuated by the peripheral injection 
of BoNT-A. These results suggest that transcytosed BoNT-A 
induces antinociception when peripheral injection of BoNT-A. 
Intracisternal administration of BoNT-A also attenuated 
the NMDA-evoked nociceptive response and c-Fos expression. 
These results suggest that the central antinociceptive effect 
of BoNT-A is mediated by the transcytosed BoNT-A or in-
hibition of trigeminal neurons. Our data demonstrated that 
centrally targeted BoNT-A might serve as a new ther-
apeutic tool for the treatment of orofacial chronic pain 
conditions.
CONFLICT OF INTEREST
  The authors report no conflict of interest.
ACKNOWLEDGEMENTS
  This research was supported by the National Research 
Foundation of Korea (NRF) and funded by the Ministry of 
354 HJ Kim, et al
Science, ICT & Future Planning (2008-0062282 and 2012M-
3A9B6055414) and by Hugel Inc . We are grateful to Hugel 
Inc. (Chuncheon, Republic of Korea) for providing BotulaxⓇ. 
REFERENCES
1. de Paiva A, Poulain B, Lawrence GW, Shone CC, Tauc L, Dolly 
JO. A role for the interchain disulfide or its participating thiols 
in the internalization of botulinum neurotoxin A revealed by 
a toxin derivative that binds to ecto-acceptors and inhibits 
transmitter release intracellularly. J Biol Chem. 1993;268: 
20838-20844.
2. Rizo J, Südhof TC. Mechanics of membrane fusion. Nat Struct 
Biol. 1998;5:839-842.
3. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting 
neuroexocytosis. Physiol Rev. 2000;80:717-766.
4. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler 
R. Treatment of tension-type headache with botulinum toxin 
type A: a double-blind, placebo-controlled study. Headache. 2000; 
40:300-305.
5. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A 
and chronic low back pain: a randomized, double-blind study. 
Neurology. 2001;56:1290-1293.
6. Sheean G. Botulinum toxin for the treatment of musculoskeletal 
pain and spasm. Curr Pain Headache Rep. 2002;6:460-469.
7. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin 
type A as a migraine preventive treatment. For the BOTOX 
Migraine Clinical Research Group. Headache. 2000;40:445-450.
8. Smuts JA, Schultz D, Barnard A. Mechanism of action of 
botulinum toxin type A in migraine prevention: a pilot study. 
Headache. 2004;44:801-805.
9. Göbel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum 
toxin A in the treatment of headache syndromes and pericranial 
pain syndromes. Pain. 2001;91:195-199.
10. Bach-Rojecky L, Lacković Z. Antinociceptive effect of botulinum 
toxin type a in rat model of carrageenan and capsaicin induced 
pain. Croat Med J. 2005;46:201-208.
11. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous admini-
stration of botulinum toxin A reduces formalin-induced pain. 
Pain. 2004;107:125-133.
12. Luvisetto S, Marinelli S, Lucchetti F, Marchi F, Cobianchi S, 
Rossetto O, Montecucco C, Pavone F. Botulinum neurotoxins 
and formalin-induced pain: central vs. peripheral effects in 
mice. Brain Res. 2006;1082:124-131.
13. Lee WH, Shin TJ, Kim HJ, Lee JK, Suh HW, Lee SC, Seo K. 
Intrathecal administration of botulinum neurotoxin type A 
attenuates formalin-induced nociceptive responses in mice. 
Anesth Analg. 2011;112:228-235.
14. Bach-Rojecky L, Lacković Z. Central origin of the antinociceptive 
action of botulinum toxin type A. Pharmacol Biochem Behav. 
2009;94:234-238.
15. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto 
Y, Sonoyama W, Kamioka H, Yamashiro T, Kuboki T, Oguma 
K. Botulinum toxin type a (150 kDa) decreases exaggerated 
neurotransmitter release from trigeminal ganglion neurons and 
relieves neuropathy behaviors induced by infraorbital nerve 
constriction. Neuroscience. 2009;159:1422-1429.
16. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The 
effects of Botulinum Toxin type A on capsaicin-evoked pain, 
flare, and secondary hyperalgesia in an experimental human 
model of trigeminal sensitization. Pain. 2006;122:315-325.
17. Borodic GE, Acquadro MA. The use of botulinum toxin for the 
treatment of chronic facial pain. J Pain. 2002;3:21-27.
18. Ahn DK, Chae JM, Choi HS, Kyung HM, Kwon OW, Park HS, 
Youn DH, Bae YC. Central cyclooxygenase inhibitors reduced 
IL-1beta-induced hyperalgesia in temporomandibular joint of 
freely moving rats. Pain. 2005;117:204-213.
19. Wang XM, Zhang ZJ, Bains R, Mokha SS. Effect of antisense 
knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the 
antinociceptive action of clonidine on trigeminal nociception in 
the rat. Pain. 2002;98:27-35.
20. Yaksh TL, Rudy TA. Chronic catheterization of the spinal suba-
rachnoid space. Physiol Behav. 1976;17:1031-1036.
21. Choi HS, Ju JS, Lee HJ, Jung CY, Kim BC, Park JS, Ahn DK. 
Effects of TNF-alpha injected intracisternally on the nociceptive 
jaw-opening reflex and orofacial formalin test in freely moving 
rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27: 
613-618.
22. Chang KH, Bai SJ, Lee H, Lee BH. Effects of acupuncture 
stimulation at different acupoints on formalin-induced pain in 
rats. Korean J Physiol Pharmacol. 2014;18:121-127.
23. Clavelou P, Pajot J, Dallel R, Raboisson P. Application of the 
formalin test to the study of orofacial pain in the rat. Neurosci 
Lett. 1989;103:349-353.
24. Yang GY, Woo YW, Park MK, Bae YC, Ahn DK, Bonfa E. 
Intracisternal administration of NR2 antagonists attenuates 
facial formalin-induced nociceptive behavior in rats. J Orofac 
Pain. 2010;24:203-211.
25. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The 
formalin test: an evaluation of the method. Pain. 1992;51:5-17.
26. Yang KY, Mun JH, Park KD, Kim MJ, Ju JS, Kim ST, Bae 
YC, Ahn DK. Blockade of spinal glutamate recycling produces 
paradoxical antinociception in rats with orofacial inflammatory 
pain. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57: 
100-109.
27. Ahn DK, Lee SY, Han SR, Ju JS, Yang GY, Lee MK, Youn 
DH, Bae YC. Intratrigeminal ganglionic injection of LPA causes 
neuropathic pain-like behavior and demyelination in rats. Pain. 
2009;146:114-120.
28. Kim MJ, Lee SY, Yang KY, Nam SH, Kim HJ, Kim YJ, Bae 
YC, Ahn DK. Differential regulation of peripheral IL-1β-induced 
mechanical allodynia and thermal hyperalgesia in rats. Pain. 
2014;155:723-732.
29. Park CK, Kim K, Jung SJ, Kim MJ, Ahn DK, Hong SD, Kim 
JS, Oh SB. Molecular mechanism for local anesthetic action 
of eugenol in the rat trigeminal system. Pain. 2009;144:84-94.
30. Kim HD, Lee HJ, Choi HS, Ju JS, Jung CY, Bae YC, Ahn DK. 
Interleukin-1 beta injected intracisternally inhibited NMDA- 
evoked behavioral response in the orofacial area of freely 
moving rats. Neurosci Lett. 2004;360:37-40.
31. Lee HJ, Choi HS, Jung CY, Ju JS, Kim SK, Bae YC, Ahn DK. 
Intracisternal NMDA produces analgesia in the orofacial 
formalin test of freely moving rats. Prog Neuropsychopharmacol 
Biol Psychiatry. 2004;28:497-503.
32. Wilcox GL. Pharmacological studies of grooming and scratching 
behavior elicited by spinal substance P and excitatory amino 
acids. Ann N Y Acad Sci. 1988;525:228-236.
33. Zhang KM, Wang XM, Peterson AM, Chen WY, Mokha SS. 
alpha2-adrenoceptors modulate NMDA-evoked responses of 
neurons in superficial and deeper dorsal horn of the medulla. 
J Neurophysiol. 1998;80:2210-2214.
34. Dolly JO, Aoki KR. The structure and mode of action of 
different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1-9.
35. Simpson LL. Kinetic studies on the interaction between botulinum 
toxin type A and the cholinergic neuromuscular junction. J 
Pharmacol Exp Ther. 1980;212:16-21.
36. Hua Y, Scheller RH. Three SNARE complexes cooperate to 
mediate membrane fusion. Proc Natl Acad Sci U S A. 2001; 
98:8065-8070.
37. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and 
botulinum neurotoxin poisoning. Prog Neurobiol. 1995;46:83-96.
38. Dutton JJ, Buckley EG. Botulinum toxin in the management 
of blepharospasm. Arch Neurol. 1986;43:380-382.
39. Matak I, Stracenski I, Lacković Z. Comparison of analgesic 
effects of single versus repeated injection of botulinum toxin 
in orofacial formalin test in rats. J Neural Transm. 2013;120: 
141-144.
40. Yoo KY, Lee HS, Cho YK, Lim YS, Kim YS, Koo JH, Yoon SJ, 
Lee JH, Jang KH, Song SH. Anti-inflammatory effects of 
botulinum toxin type a in a complete Freund's adjuvant-induced 
arthritic knee joint of hind leg on rat model. Neurotox Res. 
2014;26:32-39.
BoNT-A Reduces Trigeminal Nociception 355
41. Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AM, Luvisetto 
S, Pavone F. The analgesic effect on neuropathic pain of retro-
gradely transported botulinum neurotoxin A involves Schwann 
cells and astrocytes. PLoS One. 2012;7:e47977.
42. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat 
dorsal root ganglia neurons to Clostridium botulinum neurotoxins. 
Toxicon. 2000;38:245-258.
43. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto 
O, Caleo M. Evidence for anterograde transport and transcytosis 
of botulinum neurotoxin A (BoNT/A). J Neurosci. 2011;31: 
15650-15659.
44. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. 
Long-distance retrograde effects of botulinum neurotoxin A. J 
Neurosci. 2008;28:3689-3696.
45. Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, 
Mezzaroma E, Caruso M, Straface E, Przewlocka B, Pavone F. 
Botulinum neurotoxin type A counteracts neuropathic pain and 
facilitates functional recovery after peripheral nerve injury in 
animal models. Neuroscience. 2010;171:316-328.
46. Bach-Rojecky L, Salković-Petrisić M, Lacković Z. Botulinum 
toxin type A reduces pain supersensitivity in experimental 
diabetic neuropathy: bilateral effect after unilateral injection. 
Eur J Pharmacol. 2010;633:10-14.
